Link, Hartmut http://orcid.org/0000-0002-9659-0265
,
Diel, Ingo
Ohlmann, Carsten-H.
Holtmann, Laura
Kerkmann, Markus
Funding for this research was provided by:
Amgen GmbH Germany (AIO-SUP-0116)
Article History
Received: 18 December 2018
Accepted: 30 July 2019
First Online: 14 August 2019
Compliance with ethical standards
:
: An opinion has been obtained from the Ethics Committee of Rhineland-Palatinate, Mainz, Germany, in accordance with the guidelines and recommendations for ensuring Good Epidemiological Practice (GEP). Due to the epidemiological nature of the study, no additional opinions from ethics committees were required. All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: The study was supported by unrestricted grants from Amgen GmbH to the AIO-Studien-gGmbH of the German Cancer Society, AIO-SUP-0116/ass. The funding source did not have any access to the data and was not involved in data analysis or manuscript writing.
: Professor Link received research funding and honoraria, acted on speakers’ bureau, and/or consulted for Accord Healthcare, Amgen, Hexal-Sandoz-Novartis and TEVA Mr Kerkmann and Mrs Holtmann report payment from AIO-Studien-gGmbH, during the conduct of the study. Dr. Ohlmann reports personal fees from AMGEN, during the conduct of the study. Dr. Diel reports personal fees from Amgen, personal fees from Roche, personal fees from Hexal, outside the submitted work.